

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

ATTORNEY DOCKET NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR CONFIRMATION NO. 10/059,909 Edgar B. Cahoon 01/29/2002 BB1333 USCIP 8547 09/23/2003 23906 7590 E I DU PONT DE NEMOURS AND COMPANY **EXAMINER** LEGAL PATENT RECORDS CENTER BUI, PHUONG T BARLEY MILL PLAZA 25/1128 4417 LANCASTER PIKE **ART UNIT** PAPER NUMBER WILMINGTON, DE 19805 1638

DATE MAILED: 09/23/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Office Action Summary	10/059,909	CAHOON ET AL.
	Examiner	Art Unit
	Phuong T. Bui	1638
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM		
THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-20 is/are pending in the application.		
	·· ·	al.
· · · · · · · · · · · · · · · · · · ·		
Disposition of Claims		
4a) Of the above claim(s) is/are withdrawn from consideration.		
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>1-20</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) are subject to restriction and/or election requirement.		
Application Papers 9)☐ The specification is objected to by the Examiner.		
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.		
If approved, corrected drawings are required in reply to this Office action.		
12) The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 		
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).		
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.		
Attachment(s)		
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 N	iterview Summary (PTO-413) Paper No(s) otice of Informal Patent Application (PTO-152) ther:

Application/Control Number: 10/059,909

Art Unit: 1638

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-14, drawn to a polynucleotide, classified in class 800, subclass
 296.
 - Claims 15-19, drawn to a polypeptide, classified in class 530, subclass
 372.
 - III. Claim 20, drawn to a method of using the polynucleotide, classified in class 435, subclass 69.1.

For each of inventions I-III above, restriction to one of the following is also required under 35 USC 121. Therefore, election is required of one of inventions I-III and one of inventions (A)-(I).

- (A). SEQ ID No: 1 or a sequence encoding SEQ ID No: 2.
- (B). SEQ ID No: 3 or a sequence encoding SEQ ID No: 4.
- (C). SEQ ID No: 5 or a sequence encoding SEQ ID No: 6.
- (D). SEQ ID No: 7 or a sequence encoding SEQ ID No: 8.
- (E). SEQ ID No: 9 or a sequence encoding SEQ ID No: 10.
- (F). SEQ ID No: 11 or a sequence encoding SEQ ID No: 12.
- (G). SEQ ID No: 13 or a sequence encoding SEQ ID No: 14.
- (H). SEQ ID No: 15 or a sequence encoding SEQ ID No: 16.
- (I). SEQ ID No: 17 or a sequence encoding SEQ ID No: 18.

Application/Control Number: 10/059,909

Art Unit: 1638

The inventions are distinct, each from the other because of the following reasons:

Inventions (A)-(I) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions, represent structurally different polypeptides and the polynucleotides encoding them. Therefore, where structural identity is required, such as for hybridization or expression, the different sequences have different effects.

- 2. Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different effects. The polynucleotide is structurally, chemically, biologically and functionally distinct from the polypeptide.
- 3. Inventions II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation. The method of using the polynucleotide does not require the polypeptide.
- 4. Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as

Application/Control Number: 10/059,909

Art Unit: 1638

claimed can be used in a materially different process of using that product. The polynucleotide can also be used for hybridization purposes.

- 5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, searches, and recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 6. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phuong T. Bui whose telephone number is 703-305-1996. The examiner can normally be reached on 6:30 AM - 4:00 PM; Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on 703-306-3218. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Phuong T. Bui Primary Examiner Art Unit 1638

Page 4

ptb

September 21, 2003